JAMA Netw Open: Professor Haiqiang Mai’s team from Zhongzhong confirmed that concurrent radiotherapy and chemotherapy based on nedaplatin can be used as an effective treatment plan for patients with stage II-IVB nasopharyngeal carcinoma

We know that for patients with stage II-IVB nasopharyngeal carcinoma, NCCN guidelines recommend cisplatin-based concurrent radiotherapy and chemotherapy
.

But cisplatin has obvious toxicity, such as nephrotoxicity, gastrointestinal reaction and neurotoxicity

We know that for patients with stage II-IVB nasopharyngeal carcinoma, NCCN guidelines recommend cisplatin-based concurrent radiotherapy and chemotherapy

This is a five-year follow-up secondary analysis of an open-label, non-inferiority, multi-center randomized clinical trial, including non-keratotic stage II-IVB nasal cancer from January 16, 2012 to July 16, 2014 For patients, the median follow-up time was 78 months (IQR, 3-99 months)
.

Data analysis will be conducted from November 10, 2020 to July 8, 2021

This is a five-year follow-up secondary analysis of an open-label, non-inferiority, multi-center randomized clinical trial, including non-keratotic stage II-IVB nasal cancer from January 16, 2012 to July 16, 2014 For patients, the median follow-up time was 78 months (IQR, 3-99 months)

A total of 402 eligible participants were included in the study (median [IQR] age, 45 [18-65] years; 302 [75.

Of the 402 patients, 86 (21.

Prognostic difference analysis

Prognostic difference analysis

We performed OS, PFS, DMFS, and LRFS subgroup analysis of patients stratified by the following covariates: gender (male or female), age (45 years or ≥45 years), KPS score (70-80 or 90-100) ), disease stage (II-III or IVA-B)
.

There was no interaction between these covariates and treatment (male: HR, 1.

We performed OS, PFS, DMFS, and LRFS subgroup analysis of patients stratified by the following covariates: gender (male or female), age (45 years or ≥45 years), KPS score (70-80 or 90-100) ), disease stage (II-III or IVA-B)

Subgroup analysis

Subgroup analysis

The incidence of any grade or grade 3-4 auditory toxicity in the cisplatin group was significantly higher than that in the nedaplatin group (≥ grade 1: 82/200[41.
0%] vs 112/198[56.
6%], P = 0.
002; 3- Level 4: 21[10.
5%] vs.
35[17.
7%], P =0.
04)
.

The incidence of any grade or grade 3-4 auditory toxicity in the cisplatin group was significantly higher than that in the nedaplatin group (≥ grade 1: 82/200[41.
0%] vs 112/198[56.
6%], P = 0.
002; 3- Level 4: 21[10.
5%] vs.
35[17.
7%], P =0.
04)
.

            Adverse reactions

Adverse reactions

In summary, in the secondary analysis of this randomized clinical trial, long-term follow-up results confirmed that nedaplatin-based CCRT can be regarded as another treatment strategy for patients with type II-IVB nasopharyngeal carcinoma
.

In summary, in the secondary analysis of this randomized clinical trial, long-term follow-up results confirmed that nedaplatin-based CCRT can be regarded as another treatment strategy for patients with type II-IVB nasopharyngeal carcinoma
.

In the second analysis of this randomized clinical trial, long-term follow-up results confirmed that nedaplatin-based CCRT can be regarded as another treatment strategy for patients with type II-IVB nasopharyngeal carcinoma

Original source:

Original source:

Tang QN, Liu LT, Qi B, Guo SS, Luo DH, Sun R, Sun XS, Chen DP, Guo L, Mo HY, Wang P, Liu SL, Liang YJ, Li XY, Yang ZC, Chen QY, Mai HQ , Tang LQ.

Tang QN, Liu LT, Qi B, Guo SS, Luo DH, Sun R, Sun XS, Chen DP, Guo L, Mo HY, Wang P, Liu SL, Liang YJ, Li XY, Yang ZC, Chen QY, Mai HQ , Tang LQ.
Effect of Concurrent Chemoradiotherapy With Nedaplatin vs Cisplatin on the Long-term Outcomes of Survival and Toxic Effects Among Patients With Stage II to IVB Nasopharyngeal Carcinoma: A 5-Year Follow-up Secondary Analysis of a Randomized Clinical Trial.
JAMA Netw Open.
2021 Dec 1;4(12):e2138470.
doi: 10.
1001/jamanetworkopen.
2021.
38470.
PMID: 34928359.
Leave a message here